ENALAPRIL MALEATE, ENALAPRILAT, Doses

« »

ENALAPRIL MALEATE, ENALAPRILAT

↪ Doses - ENALAPRIL MALEATE, ENALAPRILAT Chemistry - Angiotensin-converting enzyme (ACE) inhibitors, enalapril maleate and enalaprilat arestructurally related to captopril. Enalapril is a prodrug and is converted in vivo by the liver toenalaprilat. Enalapril maleate occurs as a white to off... ↪ Read more

Doses - EDROPHONIUM CHLORIDE

↪ Description - EDROPHONIUM CHLORIDE Dogs: For presumptive diagnosis of myasthenia gravis (MG): a) Inject 0.1 - 0.2 mg/kg IV; short term increased muscle strength is seen in a positive (notnecessarily specific for MG, both false positives and negatives) test. (Shelton 1992) b) 0.11 - 0.22... ↪ Read more

EDROPHONIUM CHLORIDE

↪ Doses - EDROPHONIUM CHLORIDE Chemistry - A synthetic quanternary ammonium cholinergic (parasympathomimetic) agent, edrophonium chloride occurs as a white crystalline powder having a bitter taste. Approximately 2grams are soluble in one ml of water. The injection has a pH of approximately... ↪ Read more

Doses - EDETATE CALCIUM DISODIUM, CALCIUM EDTA

↪ Description - EDETATE CALCIUM DISODIUM, CALCIUM EDTA The manufacturer of the injectable (human) product recommends diluting the injection to aconcentration of 2 - 4 mg/ml with either normal saline or 5% dextrose when used for intravenoususe. Because the injection is painful when given IM,... ↪ Read more

EDETATE CALCIUM DISODIUM, CALCIUM EDTA

↪ Doses - EDETATE CALCIUM DISODIUM, CALCIUM EDTA Chemistry - A heavy metal chelating agent, edetate calcium disodium (CaEDTA) occurs as anodorless, white, crystalline powder or granules and is a mixture of dihydrate and trihydrate forms. Ithas a slight saline taste and is slightly... ↪ Read more

Doses - DOXYLAMINE SUCCINATE

↪ Description - DOXYLAMINE SUCCINATE Dogs: a) 1.1 - 2.2 mg/kg IM or SQ q8-12h prn (Package Insert; A-H® Injection - Coopers Animal Health) b) 1.1 - 2.2 mg/kg IM, SQ, or PO q8h (Schultz 1986)Cats: a) 1.1 - 2.2 mg/kg IM or SQ q8-12h prn (Package Insert; A-H® Injection -... ↪ Read more

DOXYLAMINE SUCCINATE

↪ Doses - DOXYLAMINE SUCCINATE Chemistry - An ethanolamine-derivative antihistamine, doxylamine succinate occurs as a white tocreamy-white powder with a characteristic odor. It has a melting range of 103-108°C and pKavalues of 5.8 and 9.3. Doxylamine succinate has solubilities of 0.5... ↪ Read more

Doses - DOXYCYCLINE CALCIUM, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE

↪ Description - DOXYCYCLINE CALCIUM, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE Dogs: For susceptible infections: a) 5 mg/kg PO or IV q12h; administer with food if GI upset occurs; avoid in young animals; avoid or reduce dose in animals with severe liver disease (Vaden and Papich 1995)... ↪ Read more

DOXYCYCLINE CALCIUM, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE

↪ Doses - DOXYCYCLINE CALCIUM, DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE Chemistry - A semi-synthetic tetracycline that is derived from oxytetracycline, doxycycline isavailable as hyclate, calcium and monohydrate salts. The hyclate salt is used in the injectable dosageform and in oral... ↪ Read more

Doses - DOXORUBICIN HCL

↪ Description - DOXORUBICIN HCL For maximum effect, doxorubicin is most commonly employed as part of a multi-drugprotocol. For more information, refer to the protocols found in the appendix or other protocolsfound in numerous references, including: Handbook of Small Animal Practice (Stann... ↪ Read more

DOXORUBICIN HCL

↪ Doses - DOXORUBICIN HCL Chemistry - An anthracycline glycoside antibiotic antineoplastic, doxorubicin HCl occurs as alyophilized, red-orange powder that is freely soluble in water, slightly soluble in normal saline, andvery slightly soluble in alcohol. The commercially available powder... ↪ Read more

Doses - DOXEPIN HCL

↪ Description - DOXEPIN HCL Dogs: For treatment of psychogenic dermatoses: 3 - 5 mg/kg PO q12h; maximum dose is 150 mg(per dog) q12h. (Shanley and Overall 1992) For antihistaminic effects in treatment of atopy: 0.5 - 1 mg/kg q12h PO (White 1994) Monitoring Parameters - 1) Efficacy; 2)... ↪ Read more